In the phase II Lung-MAP substudy S1800A presented at the 2022 ASCO Annual Meeting and simultaneously reported in the Journal of Clinical Oncology, Karen L. Reckamp, MD, and colleagues found that the combination of ramucirumab and pembrolizumab improved overall survival vs investigator’s choice of standard-of-care treatment in patients with advanced non–small cell lung cancer (NSCLC) who experienced disease progression on prior immune checkpoint inhibitor therapy.

Nearly 43% of patients with non–small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized from the lung tumors, according to results of the KRYSTAL-1 trial presented by Spira et al at the 2022 ASCO Annual Meeting. The findings were simultaneously published in The New England Journal of Medicine.

In a post hoc analysis from the phase III CROWN trial reported in the Journal of Clinical Oncology, Benjamin J. Solomon, MBBS, PhD, and colleagues found that progression-free survival and the risk of central nervous system progression were improved with lorlatinib vs crizotinib in previously untreated patients with advanced ALK-positive non–small cell lung cancer (NSCLC) with or without baseline brain metastases.

In a phase II trial (CITYSCAPE) reported in The Lancet Oncology, Byoung Chul Cho, MD, and colleagues found that the addition of tiragolumab, an inhibitor of the immune checkpoint molecule TIGIT, to atezolizumab improved objective response rate and progression-free survival in first-line treatment of patients with PD-L1–positive recurrent or metastatic non–small cell lung cancer (NSCLC).

In a retrospective cohort study reported in JAMA Network Open, Sanjay Popat, FRCP, PhD, and colleagues found that among patients initiating first-line pembrolizumab for EGFR and ALK wild-type advanced non–small cell lung cancer (NSCLC), ever-smokers had significantly better overall survival vs never-smokers.